Trial Profile
A Phase II Trial of High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Up-front Treatment of Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Cytarabine; Etoposide; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Aug 2022 Results assessing the safety and efficacy of the high-dose chemotherapy combination of bendamustine, etoposide, cytarabine, and melphalan (BeEAM) in newly diagnosed MM patients published in the Transplantation and Cellular Therapy
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 30 Aug 2021 Status changed from active, no longer recruiting to completed.